The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: A systematic review and meta-analysis of randomized controlled trials

被引:50
作者
Mazidi, Mohsen [1 ,2 ]
Rezaie, Peyman [3 ]
Karimi, Ehsan [3 ]
Kengne, Andre Pascal [4 ,5 ]
机构
[1] Chinese Acad Sci, Inst Genet & Dev Biol, Key State Lab Mol Dev Biol, Beijing, Peoples R China
[2] Univ Chinese Acad Sci IC UCAS, Int Coll, Inst Genet & Dev Biol, West Beichen Rd, Chaoyang, Peoples R China
[3] Mashhad Univ Med Sci, Sch Med, Biochem & Nutr Res Ctr, Mashhad, Iran
[4] South African Med Res Council, Noncommunicable Dis Res Unit, Cape Town, South Africa
[5] Univ Cape Town, Cape Town, South Africa
关键词
Meta-analysis; Bile acid sequestrants; Fasting blood glucose; Lipid profile; TYPE-2; DIABETES-MELLITUS; IMPROVES GLYCEMIC CONTROL; COLESEVELAM HYDROCHLORIDE; DOUBLE-BLIND; INSULIN-RESISTANCE; LDL CHOLESTEROL; THERAPY; COLESTIMIDE; COMBINATION; HCL;
D O I
10.1016/j.ijcard.2016.10.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To undertake a systematic review andmeta-analysis of prospective clinical studies to determine the effect of bile acid sequestrants (BAS) on lipid profile and blood glucose concentrations. Method: PubMed-Medline, Web of Science, Cochrane Database and Google Scholar databases were searched (up until August 2016) to identify prospective studies evaluating the impact of BASs on the cardio-metabolic profile. Random effects model meta-analysis was used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. Heterogeneity was quantitatively assessed using the I-2 index. Systematic review registration: CRD42016035973. Results: From a total of 769 entries identified, 15 studies were included in the final analysis. The meta-analysis indicated a significant reduction in fasting serum triglyceride concentrations following treatment with BASs (weighted mean difference [WMD] 0.54 mg/dL, 95% CI 0.43 to 0.65, heterogeneity p = 0.021; I-2 54.2%, n = 11 studies). The WMDs for total serum cholesterol (TC) was -1.18 mg/dL (95% CI -1.30 to -1.06, heterogeneity p = 0012; I-2 63.1%, n = 11 studies), 0.126 mg/dL (95% CI 0.02 to 0.22, heterogeneity p = 0.231; I-2 43.2%, n = 11 studies) for HDL-cholesterol, and-0.24 mg/dL (95% CI-0.35 to-0.14, heterogeneity p = 0.562; I-2 23.1%, n = 10 studies) for LDL-cholesterol, and -2.10 mg/dL (95% CI -2.84 to -1.36, heterogeneity p = 0.200; I-2 42.6%, n = 11 studies) fasting blood glucose (FBG) and -0.83% (95% CI -1.08 to -0.57, heterogeneity p = 0.856; I-2 20.9%, n = 11 studies) for HbA1c. These findings were robust in sensitivity analyses. Conclusions: This meta-analysis suggests that therapy with BAS significantly improves HDL-C, LDL-C, and glycemic markers including fasting blood glucose, HbA1c levels, while deteriorating triglyceride levels. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:850 / 857
页数:8
相关论文
共 51 条
[21]   Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation [J].
Lefebvre, Philippe ;
Cariou, Bertrand ;
Lien, Fleur ;
Kuipers, Folkert ;
Staels, Bart .
PHYSIOLOGICAL REVIEWS, 2009, 89 (01) :147-191
[22]   COLESTIPOL AT VARYING DOSAGE INTERVALS IN THE TREATMENT OF MODERATE HYPERCHOLESTEROLEMIA [J].
LYONS, D ;
WEBSTER, J ;
FOWLER, G ;
PETRIE, JC .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (01) :59-62
[23]   Colesevelam Improves Oral but Not Intravenous Glucose Tolerance by a Mechanism Independent of Insulin Sensitivity and β-Cell Function [J].
Marina, Anna L. ;
Utzschneider, Kristina M. ;
Wright, Lorena A. ;
Montgomery, Brenda K. ;
Marcovina, Santica M. ;
Kahn, Steven E. .
DIABETES CARE, 2012, 35 (05) :1119-1125
[24]   A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia [J].
McCrindle, BW ;
Helden, E ;
Cullen-Dean, G ;
Conner, WT .
PEDIATRIC RESEARCH, 2002, 51 (06) :715-721
[25]  
Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.i4086, 10.1016/j.ijsu.2010.07.299, 10.1371/journal.pmed.1000097, 10.1136/bmj.b2700, 10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]
[26]  
Mohsen Mazidi E. K., 2016, J DIABETES COMPLICAT
[27]   Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study [J].
Nueesch, Eveline ;
Trelle, Sven ;
Reichenbach, Stephan ;
Rutjes, Anne W. S. ;
Tschannen, Beatrice ;
Altman, Douglas G. ;
Egger, Matthias ;
Jueni, Peter .
BMJ-BRITISH MEDICAL JOURNAL, 2010, 341 :241
[28]   Atypical Mechanism of Glucose Modulation by Colesevelam in Patients with Type 2 Diabetes [J].
Nwose, Oliseyenum M. ;
Jones, Michael R. .
CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2013, 6 :75-79
[29]   Systematic review and meta-analysis: techniques and a guide for the academic surgeon [J].
Phan, Kevin ;
Tian, David H. ;
Cao, Christopher ;
Black, Deborah ;
Yan, Tristan D. .
ANNALS OF CARDIOTHORACIC SURGERY, 2015, 4 (02) :112-122
[30]   Comprehensive meta-analysis [J].
Pierce, Charles A. .
ORGANIZATIONAL RESEARCH METHODS, 2008, 11 (01) :188-191